Bristol-Myers Squibb EVP Karin Shanahan has engaged in a transaction involving the company's common stock on 11/01/2024. The transaction involved direct shares with a par value of $0.10. Following the transaction, Shanahan holds a total of 5,336 direct shares in the company. Additionally, Shanahan has an indirect holding of 920.24 shares through the BMS Savings and Investment Program. The nature of the indirect shares indicates a vested interest in the company's performance through an employee benefit scheme. This transaction reflects the executive's ongoing investment in Bristol-Myers Squibb and provides investors with insight into executive stock ownership at the company.

Bristol-Myers Squibb EVP Karin Shanahan has engaged in a transaction involving the company's common stock on 11/01/2024. The transaction involved direct shares with a par value of $0.10. Following the transaction, Shanahan holds a total of 5,336 direct shares in the company. Additionally, Shanahan has an indirect holding of 920.24 shares through the BMS Savings and Investment Program. The nature of the indirect shares indicates a vested interest in the company's performance through an employee benefit scheme. This transaction reflects the executive's ongoing investment in Bristol-Myers Squibb and provides investors with insight into executive stock ownership at the company.